about
HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell toleranceT-cell-receptor-like antibodies - generation, function and applications.Type I and type II Fc receptors regulate innate and adaptive immunity.Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope.Signaling by Antibodies: Recent Progress.HLA-DRB1*1501 risk association in multiple sclerosis may not be related to presentation of myelin epitopes.Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis.TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexesFcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement.Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunitySingle-cell genomic approaches for developing the next generation of immunotherapiesBCR affinity differentially regulates colonization of the subepithelial dome and infiltration into germinal centers within Peyer's patches
P50
Q33641609-5360EC9B-E4D3-440A-BAD5-60F82C523C94Q33707098-6ABFAB59-CB99-4702-89AB-91C0C974E959Q37155745-C546D744-F922-42C0-936E-3951D56E1483Q37212157-92010EAC-585D-454E-BB63-E2E2AF57A312Q37987723-38064F14-EAD3-4D30-8270-F2EB21C11A0AQ38232105-F116EE70-B886-4116-B032-9E212B95F0DFQ39088327-B138C1BB-5B7D-4080-B58C-CFF92547E9CEQ39264890-36FBBB29-B369-4B5D-A477-FA43FAF7387CQ40514970-057E0803-DD66-4630-B5D5-DEB1D4D390C5Q40742367-080669CC-443C-4557-BD32-80AC250C3B1DQ42724811-1D383EFA-5F60-4012-8510-86F96C984194Q50273596-1822B4D8-CA80-4A88-8EAE-9314619F7CD5Q51513764-CC9A64BD-F3D8-4236-B96A-36664E57ED26Q57295884-34FA6E4D-BEFA-4BE2-A43F-7D1FAF1282F2Q89519294-85F68749-7AFA-4E68-83E9-45FCBC010974Q92129411-8B2D36AE-EE8E-4D0D-A512-C837C9F0C534
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rony Dahan
@ast
Rony Dahan
@en
Rony Dahan
@es
Rony Dahan
@nl
type
label
Rony Dahan
@ast
Rony Dahan
@en
Rony Dahan
@es
Rony Dahan
@nl
prefLabel
Rony Dahan
@ast
Rony Dahan
@en
Rony Dahan
@es
Rony Dahan
@nl
P106
P21
P31
P496
0000-0002-8420-7601